ScholarIQanswers from OpenAlex & ORCID
Josep Font
ResearcherPublications, citations & collaboration network
Josep Font is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Josep Font have?
ScholarIQindexed works
Josep Font has 293 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Josep Font have?
ScholarIQcitation count
Josep Font has 23,751 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Josep Font?
ScholarIQh-index
Josep Font has an h-index of 77 in OpenAlex.
What is the i10-index of Josep Font?
ScholarIQi10-index
Josep Font has an i10-index of 190 in OpenAlex.
What is the OpenAlex record for Josep Font?
ScholarIQopenalex
The OpenAlex for Josep Font is on the source record.
What are the most-cited papers on Josep Font?
ScholarIQmost cited works
Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
Ricard Cervera, Jean‐Charles Piette, Josep Font, Munther A. Khamashta, Yehuda Shoenfeld, María Teresa Camps, Søren Jacobsen, Gabriella Lakos, Anǵela Tincani, I. Kontopoulou‐Griva, Mauro Galeazzi, Pier Luigi Meroni, Ronald H. W. M. Derksen, Philip G. de Groot, Erika Gromnica‐Ihle, Marta Baleva, Marta Mosca, Stefano Bombardieri, Frédéric Houssiau, Jean‐Christophe Gris, I. Quéré, É. Hachulla, Carlos Vasconcelos, Beate Roch, Antonio Fernández‐Nebro, Marie‐Claire Boffa, Graham R.V. Hughes, M Ingelmo
Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period
Ricard Cervera, Munther A. Khamashta, Josep Font, Gian Domenico Sebastiani, Antonio Gil, Paz Lavilla, Juan Carlos Mejía, AO. Aydintug, H Chwalińska-Sadowska, Enrique de Ramón, Antonio Fernández‐Nebro, Mauro Galeazzi, Merete Valen, Alessandro Mathieu, Frédéric Houssiau, N Caro, Paula Alba, Manuel Ramos‐Casals, M Ingelmo, Graham Hughes
Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide
Frédéric Houssiau, Carlos Vasconcelos, David D’Cruz, Gian Domenico Sebastiani, Enrique de Ramón Garrido, Maria Giovanna Danieli, Daniel Abramovicz, Daniël Blockmans, Alessandro Mathieu, Haner Di̇reskeneli̇, Mauro Galeazzi, Ahmet Gül, Yair Levy, P Petera, Rajko Popović, Radmila Petrović, Renato Alberto Sinico, Roberto Cattaneo, Josep Font, Geneviève Depresseux, Jean‐Pierre Cosyns, Ricard Cervera
Systemic Lupus Erythematosus
Ricard Cervera, Munther A. Khamashta, Josep Font, Gian Domenico Sebastiani, ANTONIO GIL, Paz Lavilla, Ines Domenech, AO. Aydintug, Anna Jędryka-Góral, Enrique de Ramón, Mauro Galeazzi, Hans‐Jacob Haga, Alessandro Mathieu, Frédéric Houssiau, M Ingelmo, Graham R.V. Hughes
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
George Βertsias, John P. A. Ioannidis, J. Boletis, Stefano Bombardieri, Ricard Cervera, C Dostál, Josep Font, I-M Gilboe, F. Houssiau, T. Huizinga, David Isenberg, C. G. M. Kallenberg, M A Khamashta, J.C. Pietté, Matthias Schneider, Josef S Smolen, Gunnar Sturfelt, Anǵela Tincani, Ronald van Vollenhoven, Caroline Gordon, Dimitrios T. Boumpas